The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Cholinesterase inhibitors as Alzheimer's therapeutics (Review)
Open accessAbstract
Alzheimer's disease (AD) is one of the most common forms of dementia. AD is a chronic syndrome of the central nervous system that causes a decline in cognitive function and language ability. Cholinergic deficiency is associated with AD, and various cholinesterase inhibitors have been developed for the treatment of AD, including naturally‑derived inhibitors, synthetic analogues and hybrids. Currently, the available drugs for AD are predominantly cholinesterase inhibitors. However, the efficacy of these drugs is limited as they may cause adverse side effects and are not able to completely arrest the progression of the disease. Since AD is multifactorial disease, dual and multi‑target inhibitors have been developed. The clinical applications and the limitations of the inhibitors used to treat AD are discussed in the present review. Additionally, this review presents the current status and future directions for the development of novel drugs with reduced toxicity and preserved pharmacological activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 1×
“The progressive synthesis and aggregation of β -amyloid (a β ), a proteolytic fragment derived from amyloid precursor protein (aPP), are additional critical factors involved in ad pathogenesis (7).”
BackgroundA 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · cited 1×
“Several drugs under development are in phase iii clinical trials, including methylthioninium, which inhibits τ phosphorylation by activating the τ phosphatases or by inhibiting τ kinases (18,19).”
BackgroundA 5-month, randomized, placebo-controlled trial of galantamine in AD
Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S., Ding, C., & the Galantamine USA- Study Group (2000) · Neurology · doi:10.1212/wnl.54.12.2269 · Cited by 921
Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase.
Harel, M., Schalk, I., Ehret-Sabatier, L., Bouet, F., Goeldner, M., Hirth, C., Axelsen, P. H., Silman, I., & Sussman, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.19.9031 · Cited by 899
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
Neuropathology of Alzheimer's Disease
Perl, D. P. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20157 · Cited by 825
Kryger, G., Silman, I., & Sussman, J. L. (1999) · Structure · doi:10.1016/s0969-2126(99)80040-9 · Cited by 757
Rogers, S. L., & Friedhoff, L. T. (1996) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000106895 · Cited by 742
A perspective on multi‐target drug discovery and design for complex diseases
Ramsay, R. R., Popovic‐Nikolic, M. R., Nikolic, K., Uliassi, E., & Bolognesi, M. L. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0181-2 · Cited by 718
Acetylcholinesterase: ‘classical’ and ‘non-classical’ functions and pharmacology
Silman, I., & Sussman, J. L. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.01.014 · Cited by 524
The importance of tau phosphorylation for neurodegenerative diseases
Noble, W., Hanger, D. P., Miller, C. C. J., & Lovestone, S. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00083 · Cited by 475
Corey-Bloom, J. (1998) · Medical Entomology and Zoology · Cited by 467
New Acetylcholinesterase Inhibitors for Alzheimer's Disease
Mehta, M., Adem, A., & Sabbagh, M. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/728983 · Cited by 436
A Controlled Trial of Tacrine in Alzheimer's Disease
Farlow, M. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03490180055026 · Cited by 398
Cognitive Reserve and the Prevention of Dementia: the Role of Physical and Cognitive Activities
Cheng, S.-T. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0721-2 · Cited by 385 · cited 1×
“However, physical exercise can decrease the rate of dementia (3).”
BackgroundStructure and Mechanism of Monoamine Oxidase
Edmondson, D. E., Mattevi, A., Binda, C., Li, M., & Hubalek, F. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043364784 · Cited by 368
Bar-On, P., Millard, C. B., Harel, M., Dvir, H., Enz, A., Sussman, J. L., & Silman, I. (2002) · Biochemistry · doi:10.1021/bi020016x · Cited by 328
Tabet, N. (2006) · Age and Ageing · doi:10.1093/ageing/afl027 · Cited by 285 · cited 1×
“Therefore, ache inhibitors are used to limit the degradation of ach. ache inhibitors are able to increase the function of neural cells by increasing the concentration of ach (6).”
MethodOral physostigmine and lecithin improve memory in Alzheimer disease
Thal, L. J., Fuld, P. A., Masur, D. M., & Sharpless, N. S. (1983) · Annals of Neurology · doi:10.1002/ana.410130504 · Cited by 284
Weinstock, M. (1999) · CNS Drugs · doi:10.2165/00023210-199912040-00005 · Cited by 278
Fernández-Bachiller, M. I., Pérez, C., González-Muñoz, G. C., Conde, S., López, M. G., Villarroya, M., García, A. G., & Rodríguez-Franco, M. I. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100329q · Cited by 268
Piazzi, L., Rampa, A., Bisi, A., Gobbi, S., Belluti, F., Cavalli, A., Bartolini, M., Andrisano, V., Valenti, P., & Recanatini, M. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0340602 · Cited by 266
Acetylcholinesterase: How is structure related to function?
Silman, I., & Sussman, J. L. (2008) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2008.05.035 · Cited by 263
Zhang, Y., Kua, J., & McCammon, J. A. (2002) · Journal of the American Chemical Society · doi:10.1021/ja020243m · Cited by 258
Galantamine in Alzheimer's disease
Mann, J., & Jones, R. W. (2001) · UWE Research Repository (UWE Bristol) · Cited by 205
Camps, P., Formosa, X., Galdeano, C., Gómez, T., Muñoz-Torrero, D., Scarpellini, M., Viayna, E., Badia, A., Clos, M. V., Camins, A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8001313 · Cited by 205
Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease
Li, Q., He, S., Chen, Y., Feng, F., Qu, W., & Sun, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.031 · Cited by 202
Camps, P., El Achab, R., Morral, J., Muñoz-Torrero, D., Badia, A., Baños, J. E., Vivas, N. M., Barril, X., Orozco, M., & Luque, F. J. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000980y · Cited by 201
Monoamine Oxidases: Certainties and Uncertainties
Tipton, K. F., Boyce, S., O'Sullivan, J., Davey, G. P., & Healy, J. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043364810 · Cited by 196
Tau-Centric targets and drugs in clinical development for the treatment of alzheimer's disease
Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B. P., Lozupone, M., Santamato, A., Zecca, C., Barulli, M. R., Bellomo, A., Pilotto, A., et al. (2016) · BioMed Research International · doi:10.1155/2016/3245935 · Cited by 195
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
Inglis, F. (2002) · PubMed · Cited by 187
Acetylcholinesterase: Mechanism of Catalysis and Inhibition
Tougu, V. (2001) · Current Medicinal Chemistry-Central Nervous System Agents · doi:10.2174/1568015013358536 · Cited by 183
Galantamine for Alzheimer's disease
Loy, C., & Schneider, L. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001747.pub2 · Cited by 178
Camps, P., Formosa, X., Galdeano, C., Muñoz-Torrero, D., Ramírez, L., Gómez, E., Isambert, N., Lavilla, R., Badia, A., Clos, M. V., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900859q · Cited by 173
Metrifonate treatment of the cognitive deficits of Alzheimer's disease
Cummings, J. L., Cyrus, P. A., Bieber, F., Mas, J., Orazem, J., Gulanski, B., & The Metrifonate Study Group* (1998) · Neurology · doi:10.1212/wnl.50.5.1214 · Cited by 172
Ogura, H., Kosasa, T., Kuriya, Y., & Yamanishi, Y. (2000) · Methods and Findings in Experimental and Clinical Pharmacology · doi:10.1358/mf.2000.22.8.701373 · Cited by 162
Rivastigmine in the treatment of Alzheimer's disease: an update
Onor, M. L., Trevisiol, M., & Aguglia, E. (2007) · Clinical Interventions in Aging · doi:10.2147/ciia.2007.2.1.17 · Cited by 161
Xie, S.-S., Wang, X.-B., Li, J.-Y., Yang, L., & Kong, L.-Y. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.03.051 · Cited by 159
Rastegari, A., Nadri, H., Mahdavi, M. R., Moradi, A., Mirfazli, S. S., Edraki, N., Moghadam, F. H., Larijani, B. A., Akbarzadeh, T., & Saeedi, M. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.10.065 · Cited by 126
Huperzine A for Alzheimer's disease
Li, J., Wu, H. M., Zhou, R., Liu, G. J., & Dong, B. R. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005592.pub2 · Cited by 122
Dvir, H., Jiang, H., Wong, D. M., Harel, M., Chetrit, M., He, X., Jin, G., Yu, G. L., Tang, X. C., Silman, I., et al. (2002) · Biochemistry · doi:10.1021/bi020151+ · Cited by 120
Pi, R., Mao, X., Chao, X., Cheng, Z., Liu, M., Duan, X., Ye, M., Chen, X., Mei, Z., Liu, P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031921 · Cited by 115
Khoobi, M., Alipour, M., Sakhteman, A., Nadri, H., Moradi, A., Ghandi, M., Emami, S., Foroumadi, A., & Shafiee, A. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.07.038 · Cited by 114
Targeting Alzheimer’s disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238
Rizzo, S., Bartolini, M., Ceccarini, L., Piazzi, L., Gobbi, S., Cavalli, A., Recanatini, M., Andrisano, V., & Rampa, A. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.01.071 · Cited by 108
Galantamine for dementia due to Alzheimer's disease
Olin, J. T., & Schneider, L. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001747 · Cited by 108
Guo, A. J. Y., Xie, H. Q., Choi, R. C. Y., Zheng, Y., Bi, C. W. C., Xu, S. L., Dong, T. T.-X., & Tsim, K. W. K. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.05.002 · Cited by 104
PHYSOSTIGMINE IN ALZHEIMER'S DISEASE
Smith, C., & Swash, M. (1979) · The Lancet · doi:10.1016/s0140-6736(79)90479-3 · Cited by 95
Yazdani, M., Edraki, N., Badri, R., Khoshneviszadeh, M., Iraji, A., & Firuzi, O. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.11.038 · Cited by 92
Luo, W., Li, Y., He, Y., Huang, S., Tan, J., Ou, T., Li, D., Gu, L., & Huang, Z. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.12.022 · Cited by 91
Isolation and characterization of endophytic huperzine A-producing fungi from Huperzia serrata
Wang, Y., Zeng, Q. G., Zhang, Z. B., Yan, R. M., Wang, L. Y., & Zhu, D. (2010) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-010-0905-4 · Cited by 91
Multitarget drugs of plants origin acting on Alzheimer’s disease
Russo, P., Frustaci, A., Del Bufalo, A., Fini, M., & Cesario, A. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320130008 · Cited by 88
Catto, M., Pisani, L., Leonetti, F., Nicolotti, O., Pesce, P., Stefanachi, A., Cellamare, S., & Carotti, A. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.10.045 · Cited by 88
Azam, F., Amer, A. M., Abulifa, A. R., & Elzwawi, M. M. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s67778 · Cited by 86
Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease
Iqbal, K., Gong, C., & Liu, F. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.870156 · Cited by 81
Physostigmine for dementia due to Alzheimer's disease
Filho, J. M. J. C., & Birks, J. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001499 · Cited by 78
Reis, J., Cagide, F., Estrada, M., Teixeira, J., Bagetta, D., Pérez, C., Uriarte, E., Oliveira, P. J., Ortuso, F., Alcaro, S., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.07.056 · Cited by 78
Metrifonate for Alzheimer's disease
López-Arrieta, J., & Schneider, L. S. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003155.pub3 · Cited by 76
Berg, L., Andersson, C. D., Artursson, E., Hörnberg, A., Tunemalm, A., Linusson, A., & Ekström, F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026039 · Cited by 76
Tang, H., Zhao, L.-Z., Zhao, H., Huang, S., Zhong, S., Qin, J., Chen, Z., Huang, Z., & Liang, H. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.08.002 · Cited by 74
Phenserine Efficacy in Alzheimer's Disease
Winblad, B. G., Giacobini, E., Frölich, L., Friedhoff, L. T., Bruinsma, G., Becker, R. E., & Greig, N. H. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101311 · Cited by 73
Donepezil: potential neuroprotective and disease-modifying effects
Jacobson, S. A., & Sabbagh, M. N. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.10.1363 · Cited by 72
The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics
Greig, N. H., Micheli, E. D., Holloway, H. W., Yu, Q.-S., Utsuki, T., Perry, T., Ingram, D. K., Deutsch, J., Lahiri, D. K., & Soncrant, T. T. (2000) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2000.00311.x · Cited by 70
Kamal, M. A., Greig, N. H., Alhomida, A. S., & Al‐Jafari, A. A. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00330-0 · Cited by 70
Zhu, J., Yang, H., Chen, Y., Lin, H., Li, Q., Mo, J., Bian, Y., Pei, Y., & Sun, H. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1430691 · Cited by 68
Korábečný, J., Musílek, K., Holas, O., Binder, J., Zemek, F., Marek, J., Pohanka, M., Opletalová, V., Dohnal, V., & Kuča, K. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.08.044 · Cited by 67
Klein, J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.7.1087 · Cited by 66
A novel anti-Alzheimer's disease drug, ladostigil
Weinreb, O., Amit, T., Bar‐Am, O., & Youdim, M. B. H. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-386467-3.00010-8 · Cited by 60
Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer’s disease therapy
Pachón-Angona, I., Refouvelet, B., Andrýs, R., Martin, H., Luzet, V., Iriepa, I., Moraleda, I., Diez‐Iriepa, D., Oset‐Gasque, M. J., Marco, J. L., et al. (2019) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1545766 · Cited by 60
Khoobi, M., Alipour, M., Moradi, A., Sakhteman, A., Nadri, H., Razavi, S. F., Ghandi, M., Foroumadi, A., & Shafiee, A. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.07.045 · Cited by 60
Jin, P., Kim, J.-A., Choi, D.-Y., Lee, Y.-J., Jung, H. S., & Hong, J. T. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-2 · Cited by 59
Luo, W., Yu, Q., Zhan, M., Parrish, D. A., Deschamps, J. R., Kulkarni, S. S., Holloway, H. W., Alley, G. M., Lahiri, D. K., Brossi, A. R., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049309+ · Cited by 55
Nordgren, I., Bengtsson, E., Holmstedt, B. R., & PETTERSSON, B. (1981) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1981.tb03256.x · Cited by 55
TAU Aggregation is a Therapeutic Target for Alzheimers Disease
Takashima, A. (2010) · Current Alzheimer Research · doi:10.2174/156720510793611600 · Cited by 54
New potential AChE inhibitor candidates
de Paula, A. A. N., Martins, J. B. L., dos Santos, M. L., Nascente, L. D. C., Romeiro, L. A. S., Areas, T. F. M. A., Vieira, K. S. T., Gambôa, N. F., Castro, N. G., & Gargano, R. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.03.045 · Cited by 52
De‐la‐Torre, P., Saavedra, L., Caballero, J., Jairo Quiroga, P., Alzate‐Morales, J. H., Cabrera, M., & Trilleras, J. E. (2012) · Molecules · doi:10.3390/molecules171012072 · Cited by 48
Early investigational drugs targeting tau protein for the treatment of Alzheimer’s disease
Anand, K., & Sabbagh, M. N. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1075002 · Cited by 44
Shah, M. S., Khan, S. U., Ejaz, S. A., Afridi, S., Rizvi, S. U. F., Haq, M. N. U., & Iqbal, J. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.11.082 · Cited by 44
Cashew Nut Shell Oil — A Renewable and Reliable Petrochemical Feedstock
Taiwo, E. A. (2015) · InTech eBooks · doi:10.5772/61096 · Cited by 43
Tweedie, D., Fukui, K., Li, Y., Yu, Q.-S., Barak, S., Tamargo, I. A., Rubovitch, V., Holloway, H. W., Lehrmann, E., Wood, W. H., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156493 · Cited by 42
Synthesis of physostigmine analogues and evaluation of their anticholinesterase activities
Zhan, Z., Bian, H.-L., Wang, J., & Shan, W. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.01.097 · Cited by 38
Ali, M. A., Yar, M. S., Hasan, M. Z., Ahsan, M. J., & Pandian, S. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.07.042 · Cited by 33
Galantamine improves olfactory learning in the Ts65Dn mouse model of Down syndrome
de Souza, F. M. S., Busquet, N., Blatner, M. J., Maclean, K. N., & Restrepo, D. (2011) · Scientific Reports · doi:10.1038/srep00137 · Cited by 30
Chufarova, N. V., Czarnecka, K., Skibiński, R., Cuchra, M., Majsterek, I., & Szymański, P. (2018) · Archiv der Pharmazie · doi:10.1002/ardp.201800050 · Cited by 28
Lopes, J. P. B., da Silva, L. A. A., Franarin, G. D. C., Ceschi, M. A., Lüdtke, D. S., Dantas, R. F., de Salles, C. M. C., Silva, F. P., Senger, M. R., Guedes, I. A., et al. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.10.003 · Cited by 28
Becker, R. E., Greig, N. H., Lahiri, D. K., Bledsoe, J. R., Majercik, S. D., Ballard, C. G., Aarsland, D., Schneider, L. S. S., Flanagan, D. R., Govindarajan, R., et al. (2018) · Current Alzheimer Research · doi:10.2174/1567205015666180110120026 · Cited by 20
Thatte, U. M. (2005) · PubMed · Cited by 9
Cited by
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789
Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging
Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638
Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation
Chen, Y., & Yu, Y. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02853-3 · Cited by 516
“These cholinesterase inhibitors and NMDA receptor antagonist memantine only temporarily relieve the symptoms of AD patients but do not delay the progression of the disease [206, 207].”
BackgroundAlzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement
Stanciu, G. D., Luca, A., Rusu, R. N., Bild, V., Beschea Chiriac, S. I., Solcan, C., Bild, W., & Ababei, D. C. (2019) · Biomolecules · doi:10.3390/biom10010040 · Cited by 297
Nimgampalle, M., Chakravarthy, H., Sharma, S., Shree, S., Bhat, A. R., Pradeepkiran, J. A., & Devanathan, V. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101994 · Cited by 207
Metadata
- Authors
- Sharma, K.
- Venue
- Molecular Medicine Reports
- Publisher
- Spandidos Publications
- Published
- 2019-06-11
- Volume
- 20
- Issue
- 2
- Pages
- 1479-1487
- ISSN
- 1791-2997 (ISSN-L)
- 1791-3004
- OpenAlex
- W2951219679
- Cited by
- 602
- References
- 89
- FWCI
- 34.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.